Roland E Kontermann Selected Research

Bispecific Antibodies

11/2021	Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
1/2021	A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
1/2021	A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.
1/2020	CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.
10/2014	Tumor-antigen-binding bispecific antibodies for cancer treatment.
4/2010	Bispecific antibodies for cancer immunotherapy: Current perspectives.
8/2007	Recombinant bispecific antibodies for cellular cancer immunotherapy.
4/2007	Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
1/2005	Recombinant bispecific antibodies for cancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roland E Kontermann Research Topics

Disease

74	Neoplasms (Cancer) 12/2022 - 08/2003
6	Melanoma (Melanoma, Malignant) 12/2022 - 01/2004
6	Neoplasm Metastasis (Metastasis) 12/2022 - 06/2012
6	Inflammation (Inflammations) 09/2021 - 02/2010
4	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2010
4	Fibrosarcoma 01/2018 - 03/2015
3	Head and Neck Neoplasms (Head and Neck Cancer) 10/2014 - 11/2010
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2018
2	Glioblastoma (Glioblastoma Multiforme) 12/2021 - 11/2018
2	Necrosis 12/2021 - 01/2019
2	Demyelinating Diseases (Demyelinating Disease) 09/2021 - 10/2019
2	Rheumatoid Arthritis 01/2021 - 04/2008
2	Fibrosis (Cirrhosis) 01/2020 - 09/2015
2	Neuralgia (Stump Neuralgia) 10/2019 - 01/2019
2	Communicable Diseases (Infectious Diseases) 03/2012 - 10/2004
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2010 - 06/2010
2	Carcinoma (Carcinomatosis) 05/2004 - 12/2003
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Central Nervous System Diseases (CNS Diseases) 09/2021
1	Stomach Neoplasms (Stomach Cancer) 01/2021
1	Wilms Tumor (Wilm's Tumor) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021
1	Neoplasm Micrometastasis 11/2020
1	Carcinogenesis 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Fatty Liver 01/2020
1	Insulin Resistance 01/2020
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020
1	Multiple Sclerosis 10/2019
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2019
1	Pain (Aches) 01/2019
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2019

Drug/Important Bio-Agent (IBA)

28	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2004
15	AntigensIBA 01/2022 - 01/2004
14	Liposomes (Liposome)IBA 10/2020 - 05/2004
13	LigandsIBA 01/2022 - 06/2012
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 07/2009
9	Bispecific AntibodiesIBA 11/2021 - 01/2005
8	Type II Tumor Necrosis Factor ReceptorsIBA 01/2022 - 10/2016
8	Peptides (Polypeptides)IBA 01/2021 - 08/2003
7	AntibodiesIBA 01/2021 - 10/2004
7	Immunoglobulin FragmentsIBA 10/2020 - 10/2008
7	EndoglinIBA 04/2020 - 03/2004
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2009
6	CytokinesIBA 11/2021 - 10/2008
5	Phosphotransferases (Kinase)IBA 12/2022 - 01/2018
5	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022 - 10/2016
4	TNF-Related Apoptosis-Inducing LigandIBA 01/2022 - 05/2014
4	Type I Tumor Necrosis Factor ReceptorsIBA 09/2021 - 10/2016
4	Immunoglobulin G (IgG)IBA 01/2021 - 01/2014
4	Single-Chain AntibodiesIBA 10/2014 - 07/2007
3	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 05/2015
3	Epithelial Cell Adhesion MoleculeIBA 11/2020 - 01/2016
3	Coloring Agents (Dyes)IBA 10/2020 - 01/2017
3	Therapeutic UsesIBA 01/2020 - 01/2018
3	Interleukin-15 (Interleukin 15)IBA 01/2019 - 06/2012
3	Monoclonal AntibodiesIBA 10/2018 - 07/2005
3	Pharmaceutical PreparationsIBA 01/2018 - 02/2015
3	Ribonucleases (Ribonuclease)IBA 05/2015 - 10/2014
3	ranpirnase (Pannon)IBA 05/2015 - 10/2014
2	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2017
2	Neuregulin-1 (Neuregulin 1)IBA 01/2022 - 01/2017
2	Death Domain ReceptorsIBA 12/2021 - 05/2014
2	Glutamic Acid (Glutamate)FDA Link 09/2021 - 01/2019
2	Granzymes (Granzyme)IBA 01/2021 - 08/2011
2	Fluorescent Dyes (Fluorescent Probes)IBA 10/2020 - 05/2016
2	human ERBB2 proteinIBA 10/2020 - 10/2012
2	EpitopesIBA 01/2020 - 01/2017
2	Tumor Biomarkers (Tumor Markers)IBA 01/2017 - 05/2015
2	Peptide Hydrolases (Proteases)FDA Link 07/2014 - 01/2005
2	Carcinoembryonic AntigenIBA 11/2010 - 09/2009
2	Small Interfering RNA (siRNA)IBA 06/2010 - 02/2010
2	Surface Antigens (Surface Antigen)IBA 11/2008 - 07/2007
1	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2022
1	histidine-rich proteinsIBA 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	Immunoglobulin E (IgE)IBA 01/2022
1	Immunoglobulin M (IgM)IBA 01/2022
1	Prolactin Receptors (Prolactin Receptor)IBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	Angiopep-2IBA 12/2021
1	CuprizoneIBA 09/2021
1	Proteolysis Targeting ChimeraIBA 01/2021
1	Histocompatibility Antigens Class IIBA 01/2021
1	Doxycycline (Periostat)FDA LinkGeneric 01/2021
1	Interleukin-10 (Interleukin 10)IBA 11/2020
1	pembrolizumabIBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 01/2020
1	birinapantIBA 11/2018
1	Melanins (Melanin)IBA 10/2018
1	Apoptosis Regulatory ProteinsIBA 01/2018

Therapy/Procedure

38	Therapeutics 01/2022 - 01/2004
12	Immunotherapy 01/2022 - 08/2007
3	Drug Therapy (Chemotherapy) 01/2020 - 02/2006
1	Injections 02/2018